Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis
File(s)oncsis201680a.pdf (2.85 MB)
Published version
Author(s)
Type
Journal Article
Abstract
Aurora kinase A (AURKA) has been implicated in the regulation of cell cycle progression, mitosis and a key number of oncogenic signaling pathways in various malignancies. However, little is known about its role in gastric cancer prognosis and genotoxic resistance. Here we found that AURKA was highly overexpressed in gastric cancer and inversely correlated with disease prognosis. Overexpression of AURKA exacerbated gastric cancer drug resistance through upregulating the expression of the anti-apoptotic protein Survivin. Conversely, we demonstrated that AURKA depletion caused a decrease in Survivin protein levels by increasing its ubiquitylation and degradation. Mass spectrometric analysis revealed that upon AURKA depletion, Survivin bound to the FBXL7 E3 ubiquitin ligase, which induced ubiquitin-proteasome degradation of Survivin. In addition, we showed that AURKA regulated FBXL7 both at the levels of transcription and translation. Moreover, proteomic analysis of nuclear AURKA-interacting proteins identified Forkhead box protein P1 (FOXP1). We next showed that AURKA was required for FBXL7 transcription and that AURKA negatively regulated FOXP1-mediated FBXL7 expression. The physiological relevance of the regulation of Survivin by AURKA through the FOXP1–FBXL7 axis was further underscored by the significant positive correlations between AURKA and Survivin expression in gastric cancer patient samples. Moreover, the AURKA depletion or kinase inhibition-induced apoptotic cell death could be reversed by Survivin ectopic overexpression, further supporting that AURKA regulated Survivin to enhance drug resistance. In agreement, inhibition of AURKA synergistically enhanced the cytotoxic effect of DNA-damaging agents in cancer cells by suppressing Survivin expression. Taken together, our data suggest that AURKA restricts Survivin ubiquitylation and degradation in gastric cancer to promote drug resistance and hence the AURKA–Survivin axis can be targeted to promote the efficacy of DNA-damaging agents in gastric cancer.
Date Issued
2017-02-20
Date Acceptance
2016-11-07
Citation
Oncogenesis, 2017, 6
ISSN
2157-9024
Publisher
Nature Publishing Group
Journal / Book Title
Oncogenesis
Volume
6
Copyright Statement
© The Author(s) 2017. ncogenesis
is an open-access journal published by
Nature Publishing
Group
. This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this article are included
in the article
’
s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need to
obtain permission from the license holder to reproduce the material. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/
is an open-access journal published by
Nature Publishing
Group
. This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this article are included
in the article
’
s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need to
obtain permission from the license holder to reproduce the material. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/
Sponsor
Cancer Research UK
Breast Cancer Now
Breast Cancer Campaign and Breakthrough Breast Cancer
Grant Number
C37/A12011
2012NovemberPhD016
2012MayPR070
Publication Status
Published
Article Number
e298